Key result
Restoration of the ACE2/Ang-(1-7)/MasR axis appears to be a promising protective therapeutic strategy for improving glycemia in type 2 diabetes mellitus.
Why the study?
Does restoration of ACE2 improve glycemia in type 2 diabetes mellitus?
Does restoration of ACE2 improve glycemia in type 2 diabetes mellitus?
Answers are grounded in this paper and cite their sources.
Restoration of ACE2 levels represents a promising therapeutic strategy for managing glycemia in type 2 diabetes by counteracting the negative effects of Ang-II and enhancing Ang-(1-7)/MasR signaling.
In spite of the novel antidiabetic drugs available on the market, type 2 diabetes mellitus (T2DM) affects nearly 25 million people in the USA and causes about 5% of all deaths globally each year. Given the rate and proportion by which T2DM is affecting human beings, it is indispensable to identify new therapeutic targets that can control the disease. Recent preclinical and clinical studies suggest that attenuating the activity of the renin-angiotensin system (RAS) could improve glycemia in diabetic patients. Angiotensin-converting enzyme 2 (ACE2) counteracts RAS overactivity by degrading angiotensin-II (Ang-II), a vasoconstrictor, to Ang-(1-7) which is a vasodilator. A decrease in ACE2 and an increase in A disintegrin and metalloproteinase (ADAM17)-mediated shedding activity have been observed with the progression of T2DM, suggesting the importance of this mechanism in the disease. Indeed, restoration of ACE2 improves glycemia in db/db and Ang-II-infused mice. The beneficial effects of ACE2 can be attributed to reduced oxidative stress and ADAM17 expression in the islets of Langerhans in addition to the improvement of blood flow to the β-cells. The advantage of ACE2 over other RAS blockers is that ACE2 not only counteracts the negative effects of Ang-II but also increases Ang-(1-7)/Mas receptor (MasR) [a receptor through which Ang-(1-7) produces its actions] signaling in the cells. Increased Ang-(1-7)/MasR signaling has been reported to improve insulin sensitivity and glycemia in diabetic animals. Altogether, ACE2/Ang-(1-7)/MasR axis of the RAS appears to be protective in T2DM and strategies to restore ACE2 levels in the disease seem to be a promising therapy for Ang-II-mediated T2DM.
No takes yet. Share an insight, caveat, or question.
Chhabra et al. (2013) conducted a review in Type 2 diabetes mellitus (T2DM). ACE2/Ang-(1-7)/MasR axis restoration was evaluated. Restoration of the ACE2/Ang-(1-7)/MasR axis appears to be a promising protective therapeutic strategy for improving glycemia in type 2 diabetes mellitus.
Synapse has enriched 10 related papers. Consider them for comparative context: